Incidence and clinical impact of coronary artery disease confirmed by coronary CT angiography in patients with interstitial lung disease

Table 2 Clinical management and outcomes of patients with ILD with and without CAD

Variables	Overall (N = 215)	CAD (N = 92)	Non-CAD (N = 123)	P-Value
Use of antiplatelet agent	75 (34.9)	70 (76.1)	5 (4.1)	< 0.001
Use of lipid lowering agent	120 (55.8)	83 (90.2)	37 (30.1)	< 0.001
Diagnostic CAG	49 (22.8)	47 (51.1)	2 (1.6)	< 0.001
Revascularization*	27 (12.6)	27 (29.3)	0 (0.0)	< 0.001
5-year rehospitalization‡	76 (49.7)	41 (55.6)	35 (44.2)	0.001
5-year all-causes mortality‡	39 (33.4)	24 (52.6)	15 (20.8)	0.001

Data are presented as the numbers (No.) and percentages (%). Analysis parameters with statistically significant differences are shown in bold
*Revascularization includes both percutaneous coronary intervention and coronary artery bypass grafting
‡5-year rehospitalization and all-cause mortality incidences are shown as numbers and percentages. Cumulative risk was calculated using Kaplan-Meier analysis, with P-values from the log-rank test, as shown in Fig. 3
ILD = interstitial lung disease, CAD = coronary artery disease; CAG = coronary angiography

ISSN: 1471-2466